Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzafatide pevedotin (formerly 5528), a Bicycle Drug Conjugate (BDC) targeting EphA2, a historically undruggable target; zelenectide pevedotin (formerly BT8009), a BDC targeting Nectin‑4, a well‑validated tumor antigen; and BT7480, a Bicycle Tumor‑Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin‑4 and agonizing CD137, in company‑sponsored clinical trials. Additionally, the company is developing Bicycle Radioconjugates (BRC) for radiopharmaceutical use ...